Juhn,
Hmm, I see you like to avoid the topic and bring up unrelated issues like black holes. You implied that the GTCB business model should be questioned because
<<Can a process that is superior to GTC produce similar quantities of complex proteins in another manner in the future?
Has anyone speculated on other means that are being developed to produce large quantifies of these complex proteins?>>
Of course these issues have been discussed many, many times. I provided specific answers why this is not the big concern for GTCB now. You simply avoided responding. I used the term putative several times to drive home a point. You want us to worry about something that hasn't happened, but more importantly, won't destroy GTCB even if it happened.
The issue of glycolsylation is relevant because GTCB has provided evidence that it makes GTCB produced monoclonal antibodies that are superior with regard to ADCC as compared to htose made by cell culture. Now, do you want to address my rebuttal to your thesis? Do you want to speculate what the superior ADCC means? Or will you simply continue to pontificate in generalities that aren't relavant to GTCB now and that lack real substance.
